ArticleFuture microbiology2026
Assessing antimicrobial resistance in Shiga toxin-producing
Article in Future microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo characterize antimicrobial resistance (AMR) patterns and temporal trends among Shiga toxin-producing PATIENTS AND
methods1,995 STEC O157 isolates collected from cases between 2010 and 2021 were analyzed. Resistance to antimicrobials was assessed, and temporal trends were evaluated using the Mann-Kendall test. Associations between AMR and demographic factors, including age and region, were examined using logistic regression models.
resultsResistance was most common to tetracycline (12.4%) and sulfisoxazole (9.9%), with temporal increases observed in resistance for these agents, along with chloramphenicol and trimethoprim-sulfamethoxazole (Mann-Kendall tau = 0.69-0.87,
conclusionsSince antimicrobials are not recommended for treating STEC O157 infections in humans, the sources of resistant strains could be foodborne, direct animal contact, the environment, or treatment for bacterial coinfections. The increase in the prevalence of AMR among STEC O157 strains in humans warrants investigation into the factors driving the emergence of resistant isolates. These findings call for an "One Health" approach for antimicrobial stewardship to mitigate AMR risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.